The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders

We have explored the molecular basis of the clinical therapeutic effect of factor Wa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII circulates as a single-chain inactive zymogen (10 nM) and a trace (similar to 10-100 pM) circulates in the active two-chain form. Empirical reconstitution (purified factors VIIa, X, IX, WI, V, prothrombin, and relipidated tissue factor) showed that plasma concentrations of factor VII (10 nM) prolong the initiation phase of thrombin generation significantly at low concentrations of tissue factor and 100 pM factor VIIa. Thus, we show for the first time that the zymogen factor VII may have a very significant inhibitory action on thrombin generation at physiologic ratios of factor VII to factor VIIa. The inhibition kinetics of factor Xa generation by low concentrations of tissue factor indicate that factor Vn inhibits the reaction by competition for the initial binding of factor VIIa to tissue factor. Physiological concentrations of factor VII also inhibit the maximal rate of thrombin generation by 100 pM factor Wa in the absence of factor VIII. Increasing the concentration of factor VIIa to 2 nM in this hemophilia A model overcame the inhibition of thrombin generation by 10 nM factor VII. Increasing the concentration up to 10 nM factor VIIa in the absence of factor VIII, completely normalized the thrombin generation profile to that observed in the presence of factor VIII and 10 nM factor VII/100 pM factor VIIa. The levels of factor VIIa that overcome the inhibitory effect of factor VII and that normalize thrombin generation in our model are consistent,vith the observed plasma levels of factor VIIa needed to manage hemophilia A. Our data strongly indicate that the therapeutic mechanism of factor VIIa in the medical treatment of hemophiliacs with inhibitors is in large part based on overcoming the inhibitory effect of factor VII on thrombin generation